

**Knobbe Martens Olson & Bear LLP***Intellectual Property Law*

550 West C Street  
Suite 1200  
San Diego CA 92101  
Tel 619-235-8550  
Fax 619-235-0178  
kmob.com

May 19, 2004  
5:20 PM

ORIGINAL WILL FOLLOW VIA:

- ☐ Mail
- ☐ Courier
- ☐ International Airmail
- ☐ Hand Delivery
- ☒ Will Not Follow
- ☐ With Enclosures
- ☐ Without Enclosures

**Facsimile Transmittal Sheet**Confidentiality Notice:

The documents accompanying this facsimile transmission contain confidential information which may be legally privileged. The information is intended only for the use of the recipient named below. If you have received this facsimile in error, please immediately notify us by telephone to arrange for return of the original documents to us; any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited.

TO: Examiner Maria B. Marvich, Ph.D.

FIRM: U.S. Patent and Trademark Office

FACSIMILE NO.: 703-872-9306

FROM: Erik T. Anderson

CLIENT CODE: UC081.001A

PAGES: 5 (INCLUDING THIS SHEET)

IF YOU DID NOT RECEIVE ALL OF THE PAGES, PLEASE CALL BACK IMMEDIATELY.

MESSAGE:

I attach possible claim amendments for discussion purposes only. We look forward to the Telephonic Interview scheduled for 1:00 p.m. (EST) on 5/20/04.

Don W. Martens  
James B. Bear  
Darrell L. Olson  
William B. Bunker  
William H. Nieman  
Arthur S. Rose  
James F. Loganek  
Ned A. Israelson  
Drew S. Hamilton  
Jerry T. Sewell  
John B. Spang, Jr.  
Edward A. Schlatter  
Gerard von Hoffmann  
Joseph R. Re  
Catherine J. Holland  
John M. Carson  
Karen Vogel Weil  
Andrew H. Simpson  
Jeffrey L. Van Hooser  
Daniel E. Allman  
Stephen C. Jensen  
Vito A. Canuso III  
William H. Shreve  
Lynda J. Zadra-Symest  
Steven J. Malepashy  
Paul A. Stewart  
Joseph F. Jennings  
Craig G. Summers  
AnneMarie Kaiser  
Bronson R. Babcock  
Thomas F. Smegal, Jr.  
Michael H. Tronholm  
Diane M. Reed  
Ronald J. Schoenbaum  
John R. King  
Frederick S. Berrella  
Nancy W. Vensko  
John P. Glezentanner  
Adeel S. Akhtar  
Thomas R. Arno  
David N. Weiss  
Daniel Hart, Ph.D.  
Douglas G. Muehlhauser  
Lori Lee Yamato  
Michael K. Friedland  
Dale C. Hunt, Ph.D.  
Richard E. Campbell  
Stacey R. Halpern  
Lee W. Henderson, Ph.D.  
Mark M. Abumori

Jon W. Gurke  
John W. Holcomb  
Joseph M. Refaman, Ph.D.  
Michael L. Fuller  
Eric M. Nelson  
Mark R. Benedict, Ph.D.  
Paul N. Conover  
Robert J. Roby  
Sabing H. Lee  
Kathleen A. Dufanay  
Joseph S. Ciafrani  
William R. Zimmerman  
Paul C. Steinhart  
Eric S. Furman, Ph.D.  
Susan M. Nafand  
James W. Hill, M.D.  
Dorothy G. Shepherd  
Glen L. Nuttall  
Tirzah Ada Lowe  
Sanjivpal S. Gill  
Rose M. Tibbassan, Ph.D.  
Michael A. Gulliana  
Mark J. Kertz  
Rabinder N. Narula  
Bruce S. Ilchikawitz, Ph.D.  
Michael S. Okamoto  
John M. Grover  
Mallory K. De Meriter  
Irfan A. Lateef  
Amy C. Christensen  
Sharon S. Ng  
Mark J. Gallagher, Ph.D.  
David G. Jankowski, Ph.D.  
Brian C. Horne  
Payson J. LeMailleur  
Sheila N. Swacop  
Ben A. Katzensilenbogen  
Linda H. Liu  
Andrew N. Merckel, Ph.D.  
David L. Hauser  
James F. Markenhoff  
Scott Loras Murray  
Andrew M. Douglas  
Marc T. Morley  
Salima A. Merani, Ph.D.  
Sam K. Tahmassebi, Ph.D.  
Christy G. Lee  
Jonathan A. Hyman  
Curtiss C. Dostler  
Joseph J. Mellon, Ph.D.

Thomas P. Krzeminski  
Sean M. Murray  
Eleanor Niu  
Valerie L. Bracken  
J. David Evered  
Perry D. Oldham  
Jerry L. Helmer, Ph.D.  
Russell M. Jeld  
Abraham W. Chuang  
Pui Tong Ho, Ph.D.  
Erik T. Anderson  
John L. Paik  
Jesse A. Rothwell  
Marco C. Baumgartner  
Danielle Klausner  
Kyle F. Schuster  
Raphael A. Gutierrez  
Damian K. Jackson  
Nathan A. Engels  
Gregory A. Hermanson  
Zi Y. Wong  
John N. Kandara  
Matthew S. Baillinger  
Davis K. Wiggins  
Darryl H. Stegmann, Ph.D.  
Lauren J. Keller  
Ted M. Cannon  
Carol M. Pitzel  
José A. Vilalta  
Sheila R. Gibson  
Andrew I. Kimmel  
Curds R. Hufmire  
Tina Chen  
Brandon Gingrich, Ph.D.  
Christopher L. Ross  
Don W. Anthony, Ph.D.  
John G. Rickenbroda  
Aaron D. Barker  
Christian A. Fox  
M. Todd Heles  
Ell A. Loois, Ph.D.  
Jennifer L. Enmon, Ph.D.  
Shusha A. Adque  
Ryan E. Melnick, Ph.D.  
Brian C. Leubitz  
Yasha S. Bourla  
Phillip M. Nelson  
Karl L. Klassen  
Jason T. Z...

Of Counsel  
Louis J. Knobbe  
Jerry R. Sailer  
Japanese Patent Atty  
Katsuhiko Arai  
Tomohisa Sugiyama

Korean Patent Atty  
Mincheol Kim  
Heungsoo Choi

Scientists & Engineers  
(Non-Lawyers)

Raimond J. Salenleke\*\*  
Khurram Rehman, Ph.D.  
Jennifer Haynes, Ph.D.  
Chao S. Chersakh, Ph.D.  
James W. Ausley\*\*  
Kirk E. Pastorian, Ph.D.  
Connie C. Tong, Ph.D.  
Susanne Jepson, Ph.D.  
Mira M. Brand\*\*  
Tiffany C. Miller\*\*  
James W. Chang, Ph.D.  
Marina L. Garvey, Ph.D.  
W. Frank Dauerer  
Lang J. McHardy\*\*  
Karen J. Lenker  
Chris Westberg, Ph.D.  
Eric B. Ivas, Ph.D.  
Raymond D. Smith, Ph.D.

\* A Professional Corporation  
† Also Bar Matter ALAW (Eng & Weiss)  
\*\* U.S. Patent Agent  
†† Also Solicitor (Eng & Weiss)

RECEIVED  
CENTRAL FAX CENTER

MAY 19 2004

Unofficial

2040 Main Street  
14th Floor  
Irvine, CA 92614  
Tel 949-760-0004

201 California Street  
Suite 1150  
San Francisco CA 94111  
Tel 415-434-4114

1901 Avenue of the Stars  
Suite 1500  
Los Angeles CA 90087  
Tel 310-551-3450

3403 Tenth Street  
Suite 700  
Riverside CA 92501  
Tel 951-781-8231

1114 Marsh Street  
San Luis Obispo CA 93401  
Tel 805-547-5380  
Fax 805-547-5380

To: Examiner Maria B. Marvich, Ph.D.

Possible Claim Amendments for discussion during Interview 5/20/04

U.S. Application No. 10/042,775

Attorney ref: UC081.001A

**NOT FOR ENTRY INTO THE FILE**

1. A method for recombinantly producing functional ataxia-telangiectasia (ATM) protein, comprising:

providing a viral vector comprising a cDNA encoding the ATM protein operably linked to a promoter;

infecting ATM deficient mammalian L3 cells with said viral vector, wherein said mammalian L3 cells are thereby made to produce functional ATM protein; and

isolating said functional ATM protein produced by said mammalian L3 cells.

2. The method of Claim 1, wherein said viral vector comprising a cDNA encoding the ATM protein operably linked to a promoter is a vaccinia viral vector.

3. ~~(cancelled) The method of Claim 1, wherein said viral vector comprising a cDNA encoding the ATM protein operably linked to a promoter is a variola viral vector.~~

4. (cancelled)

5. The method of Claim 1, wherein said promoter is a synthetic early/late viral promoter.

6. ~~(cancelled) The method of Claim 1, wherein said mammalian cells are human cells.~~

7. ~~(cancelled) The method of Claim 1, wherein said ATM deficient mammalian cells are HeLa cells.~~

8. (cancelled)

9. ~~(cancelled) The method of Claim 1, wherein said ATM deficient mammalian cells are L3 cells.~~

10. The method of Claim 1, further wherein said ATM-deficient mammalian L3 cells producing said functional ATM protein exhibit regain of ATM function.

11. The method of Claim 1 wherein isolating said functional ATM protein comprises binding an anti-ATM antibody to said ATM protein.

12. The method of Claim 1, where said cDNA encoding the ATM protein is modified to comprise a FLAG epitope.

13. The method of Claim 12, wherein isolating said functional ATM protein comprises binding an antibody specific for the FLAG epitope to said ATM protein.

14. The method of Claim 1, wherein said functional ATM protein is produced at a level of greater than 2  $\mu$ g substantially purified ATM protein per 300 grams fresh weight of host cells or host tissue.

15. The method of Claim 1, further wherein said functional ATM protein is capable of phosphorylating ATM substrates.

16. The method of Claim 15, wherein said substrates comprise p53 and PHAS-1.

17. A method for recombinantly producing functional ataxia-telangiectasia (ATM) protein, comprising:

providing a vaccinia viral vector comprising a cDNA encoding the ATM protein operably linked to a promoter;

infecting mammalian cells with said vaccinia viral vector, wherein said mammalian cells produce functional ATM protein; and

isolating said functional ATM protein produced by said mammalian cells by binding an anti-ATM antibody to the ATM protein;

wherein the yield of functional ATM protein is at least 2  $\mu$ g substantially purified ATM protein per 300 grams fresh weight of mammalian cells.

18. The method of Claim 17, wherein said the yield of functional ATM protein is greater than 5  $\mu$ g substantially purified ATM protein per 300 grams fresh weight of mammalian cells.

19. The method of Claim 17, wherein said mammalian cells are human cells.

20. (cancelled)

21. The method of Claim 17, where said cDNA encoding the ATM protein is modified to comprise a FLAG epitope.

22. (cancelled)

23. A method for recombinantly producing functional ataxia-telangiectasia (ATM) protein, comprising:

providing a vaccinia viral vector comprising a cDNA encoding the ATM protein operably linked to a promoter;

infecting mammalian cells with said vaccinia viral vector, wherein said mammalian cells produce functional ATM protein; and

isolating said functional ATM protein produced by said mammalian cells wherein said functional ATM protein is produced at a level of greater than 2 µg substantially purified ATM protein per 300 grams fresh weight of host cells or host tissue.

24. The method of Claim 23, wherein said mammalian cells are human cells.

25. The method of Claim 23 wherein said mammalian cells are L3 cells.

26. The method of Claim 23, wherein said isolating said functional ATM protein comprises binding an anti-ATM antibody to the ATM protein.

27. The method of Claim 23, where said cDNA encoding the ATM protein is modified to comprise a FLAG epitope.

28. The method of Claim 23, wherein isolating said functional ATM protein comprises binding an antibody specific for the FLAG epitope to said ATM protein.

29. (new) A method for recombinantly producing functional ataxia-telangiectasia (ATM) protein, comprising:

providing a vaccinia viral vector comprising a cDNA encoding the ATM protein operably linked to a promoter;

infecting ATM deficient mammalian cells with said vaccinia viral vector, wherein said mammalian cells are thereby made to produce functional ATM protein; and

isolating said functional ATM protein produced by said mammalian cells.

30. (new) The method of Claim 29 wherein said promoter is a synthetic early/late viral promoter.

31. (new) The method of Claim 29 wherein said mammalian cells are human cells.

32. (new) The method of Claim 29 wherein said ATM deficient mammalian cells are L3 cells.

33. (new) The method of Claim 29, wherein said ATM-deficient mammalian cells producing said functional ATM protein exhibit regain of ATM function.

34. (new) The method of Claim 29 wherein isolating said functional ATM protein comprises binding an anti-ATM antibody to said ATM protein.

35. (new) The method of Claim 29, wherein said cDNA encoding the ATM protein is modified to comprise a FLAG epitope.

36. (new) The method of Claim 35, wherein isolating said functional ATM protein comprises binding an antibody specific for the FLAG epitope to said ATM protein.

37. (new) The method of Claim 29, further wherein said functional ATM protein is capable of phosphorylating ATM substrates.

38. (new) The method of Claim 37, wherein said substrates comprise p53 and PHAS-1.

S:\DOCS\ETA\ETA-2134.DOC  
051904